Dossier assessment
Bempedoic acid (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Bempedoic acid (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Bempedoic acid (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia
Added benefit not proven in either of both research questions (drug and dietary lipid-lowering options not exhausted/exhausted except for evolocumab)
Project details
- Project no.
- A20-92
- Commission
- Commission awarded on 30.10.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.